Adaptive Biotechnologies

Directions Website Contact the business

Adaptive Biotechnologies Adaptive is an immune medicine company focused on translating the genetics of the adaptive immune system into clinical products to detect and treat disease.

Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Community Guidelines and Terms of Use
The below guidelines are intended for use on our page. It applies to our Adaptive Biotechnologies community as well as any paid social advertising that is being run through the Adaptive corporate Facebook Ads Manager. This is the official page for Adaptive Biotechnologies. It is intended to provide a forum for patients, caregivers, advocates, customers, and those who want to learn more about Adaptive, our products and services. We encourage you to participate and share your thoughts. Because we work in a heavily regulated industry, we want to make sure that all discussion stays on topic and is appropriate for the community. In certain instances, your posts may not be published to our timeline or within any comment section associated with the Adaptive Biotechnologies profile based on the following guidelines. They may not be published if they:

Do not comply with Facebook’s Terms of Use.
- Include offensive language, inappropriate, racist, sexist or discriminatory remarks.
- Include disparaging remarks or personal attacks on other users.
- Share personal information, such as phone number, email address or home address.
- Share proprietary, confidential, sensitive, or nonpublic information.
- Promote products, offers, solicit money or attempt to recruit other community members.
- Violate any copyright or intellectual property.
- Request or offer advice on personal medical matters. Please consult your physician with any questions or concerns regarding personal matters of health and treatment.
- Contain a link without any context.
- Contain any information that is false or misleading.
- Perceived as disruptive, off topic, spam, and/or excessively repetitive. Updates to this page are managed by Adaptive Biotechnologies. Please note that any content provided on the Adaptive page is for information purposes only and is not intended to be a substitute for medical advice from a healthcare professional. Always visit or talk to a qualified healthcare professional regarding any medical condition and questions about your health and treatments. The Adaptive Facebook page contains comments posted by members of the public that/which do not reflect the views of Adaptive Biotechnologies. Adaptive Biotechnologies does not verify, approve, or endorse the comments or any information posted by visitors on this page, does not warrant their accuracy, and assumes no responsibility or liability arising from content of the page or for any error, omission, defamation, libel or slander. Caution should be used before relying on any statements or opinions expressed herein. Please visit www.adaptivebiotech.com for information on Adaptive Biotechnologies’ operations, immune medicine platform, and business areas of focus. We reserve the right to block users from this page who violate these Terms of Use. We reserve the right to remove this page and its contents at any time. Please check often for updates, as we reserve the right, at our sole discretion, to modify these Terms of Use, at any time. Your use of this page indicates your acceptance of the Terms of Use and any revisions to these terms.

82 Adapters. Nearly $60,000 raised. One shared goal: cure cancer faster.As Obliteride fundraising season comes to a clos...
10/14/2026

82 Adapters. Nearly $60,000 raised. One shared goal: cure cancer faster.

As Obliteride fundraising season comes to a close, we’re proud of Team Adaptive for showing up, riding strong and rallying support for lifesaving cancer research at Fred Hutch. Thank you to everyone who helped make this year’s effort possible.

10/08/2026

The science behind clonoSEQ® continues to build.

With more than 300 peer-reviewed publications across ALL, CLL, DLBCL, MCL and multiple myeloma, clonoSEQ is one of the most extensively studied MRD tests in blood cancer. As the evidence base grows, clonoSEQ is helping clinicians better understand disease burden, assess response and inform care decisions throughout the patient journey.

Adaptive has achieved My Green Lab® Certification at the Gold level for our Minimal Residual Disease R&D lab.The certifi...
10/05/2026

Adaptive has achieved My Green Lab® Certification at the Gold level for our Minimal Residual Disease R&D lab.

The certification reflects meaningful, measurable work across MRD R&D, including a full lab evaluation, updated practices to help reduce waste, conserve water and lower energy use, and staff training to support long-term environmental stewardship.

For us, sustainability is part of how we pursue growth with integrity, innovate boldly, and care for the communities and ecosystems that make our work possible.

We’re proud of the team members who helped make this achievement possible and continue to advance more sustainable science at Adaptive.

For many people living with multiple myeloma, the word “cure” has long felt out of reach. A new consensus definition pre...
09/25/2026

For many people living with multiple myeloma, the word “cure” has long felt out of reach. A new consensus definition presented by global myeloma experts at the International Myeloma Society Annual Meeting marks an important moment for the patient community.

The definition outlines rigorous criteria for when long-term remission may be considered a cure, including remaining off myeloma treatment for five years, sustained MRD-negative results and advanced imaging showing no evidence of disease.

This progress reflects how far myeloma care has come, from therapies that can help more patients achieve deep, lasting remissions to testing that can help show whether those remissions have endured over time.

Learn more about the new consensus definition and the role of MRD testing: https://adaptivebio.tech/jfy

This week MRD testing took a major step forward in multiple myeloma care.Updated NCCN® Guidelines include a dedicated pa...
09/17/2026

This week MRD testing took a major step forward in multiple myeloma care.

Updated NCCN® Guidelines include a dedicated page on measurable residual disease (MRD) with a framework for testing timepoints, and identify 10⁻⁶ as the preferred sensitivity and name clonoSEQ® as an FDA-cleared assay for MRD assessment.

This update can help support more informed conversations between patients and their care teams about disease status, treatment decisions, and ongoing monitoring.

Read more: https://adaptivebio.tech/98m

According to Blood Cancer United, approximately every 3 minutes, someone in the U.S. is diagnosed with leukemia, lymphom...
09/01/2026

According to Blood Cancer United, approximately every 3 minutes, someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma. That represents more than 190,000 people each year, with more than 1.7 million people living with or in remission from a blood cancer.

Blood cancers can affect the blood, bone marrow and immune system, often creating complex treatment decisions. Because these diseases can change over time or return after initial remission, having a meaningful, clear picture of each person’s unique disease can help patients and their care teams better prepare for what’s ahead.

At Adaptive, we’re committed to helping provide the insights needed to support confident, informed decisions along that journey. By empowering a deeper understanding of blood cancers, we are changing what’s possible for patients.

Adaptive has been recognized by U.S. News & World Report on four of its 2026–2027 Best Companies to Work For lists:• Ove...
08/28/2026

Adaptive has been recognized by U.S. News & World Report on four of its 2026–2027 Best Companies to Work For lists:
• Overall
• Healthcare and Research
• West
• Supporting Family Caregiving

A culture of belonging helps Adapters grow their careers and do their best work for patients.
Thank you to every Adapter who brings our culture to life.

Learn more: https://adaptivebio.tech/sfj

This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to...
08/07/2026

This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to learn why Chris, Christine and Amanda .

07/27/2026

clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.

What’s changed:
• Broad payer alignment and coverage across lymphoid cancers
• Integration directly into clinical workflows
• Simpler ordering and routine testing cadence

🎥 How access and workflow are enabling MRD at scale

07/08/2026

As MRD adoption accelerates, clinical practice is evolving—especially in the community.

Not every setting has routine access to bone marrow assessment. At the same time, newer therapies—like bispecifics—are moving into outpatient care, making monitoring more important than ever.

What’s emerging is a more practical approach:
• Peripheral blood as a non-invasive approach to monitor patients’ MRD status over time
• Interpreting MRD results to guide when to reflex to marrow
• MRD status to inform how long and how often therapies are used

🎥 Jay Patel, Dir., Medical Affairs, on how clonoSEQ® is being leveraged in the community setting

Address

1165 Eastlake Avenue E
Seattle, WA
98109

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Alerts

Be the first to know and let us send you an email when Adaptive Biotechnologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Adaptive Biotechnologies:

Shortcuts

Share